Frequent or large adjustments may indicate poor initial valuation or integration challenges, while stability suggests disciplined M&A execution.
Represents the net changes to the carrying value of goodwill resulting from purchase price allocations, measurement peri...
Commonly reported by large-cap firms with active M&A strategies, often found in the notes to consolidated financial statements.
other_goodwill_purchase_accounting_adjustments| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 |
|---|---|---|---|---|---|---|---|---|
| Prescription Technology Solutions | -$2.00M | -$2.00M | — | — | — | $0.00 | $0.00 | -$1.00M |
| Corporate | $7.25M | $7.25M | $7.25M | $7.25M | -$29.00M | — | — | — |
| International | — | — | $0.00 | $0.00 | $0.00 | — | — | — |
| Medical-Surgical Solutions | — | — | — | $83.00M | $0.00 | $0.00 | $0.00 | $0.00 |
| North American Pharmaceutical | $1.25M | $1.25M | — | — | — | — | $0.00 | $0.00 |
| Oncology & Multispecialty | -$12.75M | -$12.75M | — | — | — | — | -$6.00M | — |
| U.S. Pharmaceutical | — | — | $0.00 | $8.00M | $29.00M | — | — | — |
| Total | — | — | — | — | — | — | — | — |
Corporate, International, U.S. Pharmaceutical were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.